Core Viewpoint - Reap Bio (300119.SZ) has recently obtained a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs, indicating progress in its product development and regulatory approval process [1]. Group 1: New Drug Registration - Reap Bio's subsidiary, South China Agricultural University Biological Pharmaceutical Co., Ltd. (referred to as "South China Bio"), has successfully registered two diagnostic reagent products as veterinary drug products [1]. - The company has also received approval for two vaccine products, which have passed the production strain change review by the Ministry of Agriculture and Rural Affairs [1]. Group 2: Details of New Veterinary Drugs - The newly registered veterinary drugs include: - Recombinant Cat Interferon ω (lyophilized type) developed by Reap Bio and Zhongke Baike (Tianjin) Biological Pharmaceutical Co., Ltd. [2] - Avian Influenza Virus H7 subtype (rLN79 strain) developed by South China Agricultural University and other partners [2]. - Additionally, two inactivated vaccines for avian influenza have been applied for, including: - Bivalent inactivated vaccine for Avian Influenza Virus (H5N6 rHN503 strain + H5N1 rHN504 strain) [2]. - Quadrivalent inactivated vaccine for Avian Influenza Virus (H5N6 rHN503 strain + H5N1 rHN504 strain, H7N9 rHN705 strain + rHN706 strain) [2].

证券代码：300119 证券简称：瑞普生物 公告编号：2025-073 瑞普生物股份有限公司 关于五种兽药产品获农业农村部批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《兽药管理条例》和《兽药注册办法》的规定，瑞普生物股份有限公司 （以下简称"公司"）近日获得由农业农村部核发的《新兽药注册证书》，子公 司广州市华南农大生物药品有限公司（以下简称"华南生物"）研发的 2 款诊断 试剂产品获批兽药产品注册，2 款疫苗产品通过农业农村部生产毒种变更备案审 查。 详情如下： 本产品为 H7N9 亚型高致病性禽流感病毒疫苗的专用诊断试剂，是开展 H7N9 亚型禽流感疫苗免疫效果评估、疫情监测、流行病学调查及进出口检疫的 必备工具，对禽流感的有效防控、保障养禽业健康发展和公共卫生安全具有重大 意义。 （一）兽药注册情况 | 新兽药名称 | | 研制单位 | 类别 | 新兽药注册证书号 | | --- | --- | --- | --- | --- | | 重组猫干扰素ω（冻干型） | | 瑞普生物股份有限公司、中科拜 | 二类 | （2025）新兽药证字 ...

Market Overview - On September 16, the animal health sector declined by 0.41%, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Stock Performance - Key stocks in the animal health sector showed mixed performance, with the following notable movements: - Xianfeng Holdings (002141) increased by 2.27% to close at 4.06 [1] - Haili Biological (603718) rose by 1.27% to 7.17 [1] - *ST Lvkang (002868) fell by 4.34% to 23.81, leading the decline [2] - The trading volume and turnover for selected stocks were significant, with Xianfeng Holdings achieving a turnover of 1.02 billion [1] Capital Flow Analysis - The animal health sector experienced a net outflow of 15.97 million from institutional investors, while retail investors saw a net inflow of 11.29 million [2][3] - Notable capital flows included: - Biological Shares (600201) had a net inflow of 12.28 million from institutional investors [3] - *ST Lvkang (002868) saw a net outflow of 2.89 million from institutional investors [3] - Retail investors contributed positively to several stocks, including a net inflow of 12.59 million into Shenyuan Biological (688098) [3]

Core Insights - The animal health sector experienced a 1.14% increase on September 15, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Stock Performance - BioShares (600201) closed at 8.82, up 7.17% with a trading volume of 624,100 shares and a turnover of 539 million yuan [1] - Dayu Biological (871970) closed at 11.50, up 6.09% with a trading volume of 124,300 shares and a turnover of 139 million yuan [1] - Other notable performers include: - Jinhai Biological (002688) at 7.20, up 3.00% [1] - Ruipu Biological (300119) at 21.98, up 1.76% [1] - Zhongmu Co. (600195) at 7.50, up 1.63% [1] Capital Flow - The animal health sector saw a net outflow of 25.577 million yuan from institutional investors, while retail investors contributed a net inflow of 6.5625 million yuan [2] - The capital flow for individual stocks indicates: - Jinhai Biological had a net inflow of 32.1651 million yuan from institutional investors [3] - Zhongmu Co. had a net inflow of 6.8986 million yuan from institutional investors [3] - Ruipu Biological experienced a net outflow of 1.1475 million yuan from institutional investors [3]

Group 1 - The company announced on September 12 that it has incorporated cost reduction targets into its budget through a closed-loop management of all cost elements, aiming to achieve cost reduction and efficiency improvement [2] - The core focus of the company is "value-driven," and it is fully committed to advancing lean transformation and implementing a comprehensive closed-loop operational management system [2] - The company is concentrating on four key areas: centralized procurement, process optimization, lean management, and workforce efficiency, to reshape its profit model through lean cost reduction and value innovation [2] Group 2 - The company has achieved significant results in enhancing production management levels, supply chain efficiency, and product quality through its initiatives [2]

Core Viewpoint - Reap Bio (300119) announced on September 12 that as of September 10, 2025, the total number of shareholders is approximately 26,000 [1] Company Summary - Reap Bio has reported a total shareholder count of about 26,000 as of the specified date [1]

Core Viewpoint - The company, Reap Bio (300119), announced its share repurchase and dividend distribution plans, highlighting its commitment to returning value to shareholders through significant cash dividends and stock repurchases [1] Group 1: Share Repurchase - In 2023 and 2024, the company plans to repurchase a total of 10.68 million shares [1] - The total amount allocated for the share repurchase is 190 million RMB [1] Group 2: Dividend Distribution - Since its listing, the company has distributed a total of 1.371 billion RMB in cash dividends [1] - The average dividend payout ratio stands at 44.32% [1] - The company has executed four stock splits, resulting in a 5.27 times expansion of its share capital compared to before its initial public offering [1]

Group 1 - The company, Ruipeng Biotech (300119), announced on September 12 that it will provide information regarding the operation of Ruipeng Pet Hospital through official channels only [1]

Core Insights - The company announced three key initiatives to enhance the quality and efficiency of its API (Active Pharmaceutical Ingredient) segment [1] Group 1: Cost Reduction - The company aims to deepen lean cost reduction by optimizing production processes and enhancing centralized procurement management to effectively lower unit production costs [1] Group 2: Market Expansion - The company plans to accelerate its overseas market expansion and continue to increase its export share [1] Group 3: Product Optimization - The company intends to optimize its product structure by increasing the proportion of high-margin products, with plans to launch new products such as hydrochloride vonoprazan dihydrate and cefotaxime crystals in the second half of the year to enrich its high-value product matrix and improve overall profitability [1]

Core Viewpoint - The company emphasizes the importance of its stock price alignment with the ChiNext Index, indicating a strong focus on market performance and investor sentiment [1] Financial Performance - In the first half of 2025, the company expects revenue of 1.708 billion yuan and a net profit attributable to shareholders of 257 million yuan, representing year-on-year growth of 20.53% and 57.59% respectively, highlighting robust earnings growth [1] Business Strategy - The company has a solid business layout in "economic animal biological products + pet medical services," which is believed to provide long-term value that the market will recognize [1]